Drug intelligence / Profile preview

lanreotide + metformin

Development stage: Unknown
Modality: Peptides, Small Molecules
Administration: Subcutaneous, Oral

Overview

A combination therapy consisting of lanreotide, a somatostatin analog, and metformin, an antidiabetic medication. This combination has shown promising antitumor activity in both diabetic and non-diabetic patients with well-differentiated neuroendocrine tumors (WDNETs) of the gastrointestinal or thoracic tract. The MetNET-2 trial demonstrated that this combination is safe and well-tolerated with a median progression-free survival of 24 months.

Other names: Lanreotide and MetforminLanreotide 120 mg ATG + Metformin

Targets

ND1 (Mitochondrial electron transport chain complex I)AMPK (Adenosine monophosphate–activated protein kinase)SSTR5 (Somatostatin receptor 5)SSTR2 (Somatostatin receptor type 2)

Beyond the preview

Go deeper on lanreotide + metformin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lanreotide + metformin.

Explore the full profile